JUL 10, 2019 5:52 PM PDT

New anticancer agent discovered

A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent that targets the MYC gene, which is overexpressed in cancer and is associated with almost every process of the disease. While scientists have known for decades the MYC oncogene is behind most types of cancer, is continues to be difficult to regulate; the finding of these MYC promoter G-quadruplex stabilizers could, therefore, have significant implications for how we treat cancer patients.

The research was supported by the National Cancer Institute and the National Institutes of Health and has the potential to aid in treating almost every kind of cancer, according to the authors.

"We are striving to discover effective anticancer agents," said Mark Cushman, one of the leaders of the research team. "The ability to incorporate MYC promoter G-quadruplex stabilizing activity into existing topoisomerase I inhibitors has shown promise in making them more potent as anticancer agents and in making cancer cells less likely to become resistant to them."

The anticancer agents that the team discovered are called indenoisoquinoline MYC promoter G-quadruplex stabilizers. In addition to their effects on MYC, some of these agents also are able to inhibit topoisomerase I, an enzyme produced in greater amounts in cancer cells that facilitates DNA replication.

Researchers have found new anticancer agents to downregulate the MYC gene. Photo: Pixabay

This discovery with MYC will also help aid in several current ongoing clinical trials that are testing three other anticancer agents found by Cushman and his team in the past.

"Targeting promoter G-quadruplexes offers a relatively new and exciting strategy to inhibit the critical oncogene expression in cancer cells," said Danzhou Yang, who led the research with Cushman. "We hope to combine the potency of the DNA-targeted drugs and selectivity of molecular-targeted approaches for new cancer therapeutics."

Sources: Science Daily, Journal of the American Chemical Society

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 09, 2020
Cancer
Genetic counseling for prostate cancer testing goes telehealth
JUN 09, 2020
Genetic counseling for prostate cancer testing goes telehealth
Genetic testing for prostate cancer in men is not yet commonplace, despite the positive impact that it could have on dec ...
JUN 18, 2020
Cancer
The Importance of Timing in the Standard Treatment of Glioma
JUN 18, 2020
The Importance of Timing in the Standard Treatment of Glioma
Glioblastomas, the most common form of brain cancer, are very aggressive and have a standard three-stage treatment. The ...
JUL 27, 2020
Genetics & Genomics
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
JUL 27, 2020
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
A new computational tool was created by scientists at CHOP and it has now revealed new mutations that are linked to five ...
JUL 30, 2020
Cardiology
Protecting the Heart Against Cardiotoxicity
JUL 30, 2020
Protecting the Heart Against Cardiotoxicity
Doxorubicin is a potent chemotherapy drug used for many different cancers. Unfortunately, like all chemotherapies, doxor ...
AUG 10, 2020
Cancer
What fireflies' bioluminescence can teach us about mitochondria and cancer
AUG 10, 2020
What fireflies' bioluminescence can teach us about mitochondria and cancer
Researchers have developed a technique to measure mitochondria activity in cells using a molecule from fireflies. The me ...
AUG 12, 2020
Cancer
Genomic study of cervical cancers in sub-Saharan Africa
AUG 12, 2020
Genomic study of cervical cancers in sub-Saharan Africa
A first-of-its-kind study provides a comprehensive genomic study of cervical cancers in sub-Saharan Africa. Sub-Saharan ...
Loading Comments...